Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk
Introduction: Triple-negative breast cancer (TNBC) is group of heterogeneity caner. Despite majority of them had the unfavorable prognosis, a subset of patients who do not receive chemotherapy exhibit a good prognosis. Biomarkers are required to recognize these group of pateints and improve the curr...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | Breast |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977625000189 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832540439800971264 |
|---|---|
| author | Xinyu Ren Tong Zhou Yu Song Huanwen Wu Jeff Chou Lance D. Miller Zhiyong Liang Songjie Shen |
| author_facet | Xinyu Ren Tong Zhou Yu Song Huanwen Wu Jeff Chou Lance D. Miller Zhiyong Liang Songjie Shen |
| author_sort | Xinyu Ren |
| collection | DOAJ |
| description | Introduction: Triple-negative breast cancer (TNBC) is group of heterogeneity caner. Despite majority of them had the unfavorable prognosis, a subset of patients who do not receive chemotherapy exhibit a good prognosis. Biomarkers are required to recognize these group of pateints and improve the current therapeutic strategies for them. Methods: A retrospective analysis of 997 patients with TNBC from three datasets including 188 case of Peking Union Medical College Hospital (PUMCH) and two TNBC datasets from published cohort studies(279 case of Affy-set, 530 case of GSE set) was conducted. Intrinsic subtypes (basal-like, immune-enhanced, human epidermal growth factor receptor-2 [HER2]-enriched and luminal A/B) and tumor environmental immunity were evaluated using expression profiles of a 72-gene panel. Association of intrinsic subtype and immunity score with distant metastasis-free survival (DMFS) and overall survival (OS) was analyzed. Results: Five intrinsic subtypes were identified in the patients with TNBC, comprising 64 % basal-like, 19 % immune-enhanced, 11 % HER2-enriched, 5 % luminal A, and 2 % luminal B. In the absence of adjuvant chemotherapy (ACT), Luminal A and immune-enhanced subtypes showed better DMFS than basal-like, HER2-enriched, and luminal B subtypes(P = 0.35). Significantly good OS was observed in luminal A and immune-enhanced subtypes compared to basal-like and HER2-enriched subtypes (P < 0.05). So two subtype groups were further classified as low-risk subtypes, including luminal A and immune-enhanced, and high-risk subtypes, including basal-like, HER2-enriched, and luminal B. Except for the immune-enhanced subtype, each subtype was further sorted and grouped according to immunity score, istrong and iweak. Significant improvements in both DMFS and OS were observed in patients with istrong compared with those with iweak(P = 0.01 and 0.0051 respectively). When combining intrinsic subtype and immunity status to predict the benefit from ACT, all high-risk subtype patients demonstrated improved DMFS(P = 0.075) and OS(P < 0.0001), with istrong patients exhibiting greater benefit; low-risk subtype plus iweak patients showed marginal benefit, whereas low-risk subtype plus istrong patients demonstrated least benefit from ACT. Conclusion: Intrinsic subtype and immunity score is good prognostic biomarkers for patients with TNBC in the absence of chemotherapy. Combined intrinsic subtype and immunity evaluation could identify patients with TNBC who do not benefit from chemotherapy. |
| format | Article |
| id | doaj-art-128fed04551f45ca89470fb9192a6096 |
| institution | Kabale University |
| issn | 1532-3080 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Breast |
| spelling | doaj-art-128fed04551f45ca89470fb9192a60962025-02-05T04:31:08ZengElsevierBreast1532-30802025-04-0180103889Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low riskXinyu Ren0Tong Zhou1Yu Song2Huanwen Wu3Jeff Chou4Lance D. Miller5Zhiyong Liang6Songjie Shen7Department of Pathology, State Key Laboratory of Complex Severe and Rare Disease, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Oncology, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, ChinaDepartment of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaDepartment of Pathology, State Key Laboratory of Complex Severe and Rare Disease, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaComprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston-Salem, NC, USAComprehensive Cancer Center, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA; Department of Cancer Biology, Wake Forest School of Medicine, Medical Center Blvd, Winston Salem, NC, 27157, USADepartment of Pathology, State Key Laboratory of Complex Severe and Rare Disease, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, ChinaIntroduction: Triple-negative breast cancer (TNBC) is group of heterogeneity caner. Despite majority of them had the unfavorable prognosis, a subset of patients who do not receive chemotherapy exhibit a good prognosis. Biomarkers are required to recognize these group of pateints and improve the current therapeutic strategies for them. Methods: A retrospective analysis of 997 patients with TNBC from three datasets including 188 case of Peking Union Medical College Hospital (PUMCH) and two TNBC datasets from published cohort studies(279 case of Affy-set, 530 case of GSE set) was conducted. Intrinsic subtypes (basal-like, immune-enhanced, human epidermal growth factor receptor-2 [HER2]-enriched and luminal A/B) and tumor environmental immunity were evaluated using expression profiles of a 72-gene panel. Association of intrinsic subtype and immunity score with distant metastasis-free survival (DMFS) and overall survival (OS) was analyzed. Results: Five intrinsic subtypes were identified in the patients with TNBC, comprising 64 % basal-like, 19 % immune-enhanced, 11 % HER2-enriched, 5 % luminal A, and 2 % luminal B. In the absence of adjuvant chemotherapy (ACT), Luminal A and immune-enhanced subtypes showed better DMFS than basal-like, HER2-enriched, and luminal B subtypes(P = 0.35). Significantly good OS was observed in luminal A and immune-enhanced subtypes compared to basal-like and HER2-enriched subtypes (P < 0.05). So two subtype groups were further classified as low-risk subtypes, including luminal A and immune-enhanced, and high-risk subtypes, including basal-like, HER2-enriched, and luminal B. Except for the immune-enhanced subtype, each subtype was further sorted and grouped according to immunity score, istrong and iweak. Significant improvements in both DMFS and OS were observed in patients with istrong compared with those with iweak(P = 0.01 and 0.0051 respectively). When combining intrinsic subtype and immunity status to predict the benefit from ACT, all high-risk subtype patients demonstrated improved DMFS(P = 0.075) and OS(P < 0.0001), with istrong patients exhibiting greater benefit; low-risk subtype plus iweak patients showed marginal benefit, whereas low-risk subtype plus istrong patients demonstrated least benefit from ACT. Conclusion: Intrinsic subtype and immunity score is good prognostic biomarkers for patients with TNBC in the absence of chemotherapy. Combined intrinsic subtype and immunity evaluation could identify patients with TNBC who do not benefit from chemotherapy.http://www.sciencedirect.com/science/article/pii/S0960977625000189Triple-negative breast cancerIntrinsic subtypeImmunityAdjuvant chemotherapy |
| spellingShingle | Xinyu Ren Tong Zhou Yu Song Huanwen Wu Jeff Chou Lance D. Miller Zhiyong Liang Songjie Shen Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk Breast Triple-negative breast cancer Intrinsic subtype Immunity Adjuvant chemotherapy |
| title | Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk |
| title_full | Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk |
| title_fullStr | Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk |
| title_full_unstemmed | Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk |
| title_short | Intrinsic subtype and immunity score in identification of triple-negative breast cancer at low risk |
| title_sort | intrinsic subtype and immunity score in identification of triple negative breast cancer at low risk |
| topic | Triple-negative breast cancer Intrinsic subtype Immunity Adjuvant chemotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S0960977625000189 |
| work_keys_str_mv | AT xinyuren intrinsicsubtypeandimmunityscoreinidentificationoftriplenegativebreastcanceratlowrisk AT tongzhou intrinsicsubtypeandimmunityscoreinidentificationoftriplenegativebreastcanceratlowrisk AT yusong intrinsicsubtypeandimmunityscoreinidentificationoftriplenegativebreastcanceratlowrisk AT huanwenwu intrinsicsubtypeandimmunityscoreinidentificationoftriplenegativebreastcanceratlowrisk AT jeffchou intrinsicsubtypeandimmunityscoreinidentificationoftriplenegativebreastcanceratlowrisk AT lancedmiller intrinsicsubtypeandimmunityscoreinidentificationoftriplenegativebreastcanceratlowrisk AT zhiyongliang intrinsicsubtypeandimmunityscoreinidentificationoftriplenegativebreastcanceratlowrisk AT songjieshen intrinsicsubtypeandimmunityscoreinidentificationoftriplenegativebreastcanceratlowrisk |